Subtyping of gliomas of various WHO grades by the application of immunohistochemistry.
Subtyping of gliomas of various WHO grades by the application of immunohistochemistry.
复制标题
DOI：
10.1111/his.12252
复制
发表时间：
2014-02
期刊：
影响因子：
6.4
通讯作者：
Alafuzoff I
中科院分区：
文献类型：
--
作者：
Popova SN;Bergqvist M;Dimberg A;Edqvist PH;Ekman S;Hesselager G;Ponten F;Smits A;Sooman L;Alafuzoff I
2010年，通过分子遗传学分析确定了多形性胶质母细胞瘤（GBM）的四种亚型（经典型、前神经型、间质型和神经型）。本研究的目的是评估神经胶质瘤是否可以独立于类型和级别细分为基于蛋白质的亚型。一个组织芯片（TMA）的方法被应用到将组织样本的低级别和高级别胶质瘤到五个TMA。采用免疫组织化学（IHC）评估表皮生长因子受体（EGFR）、CD 44、c-MER原癌基因酪氨酸激酶（MERTK）、血小板衍生生长因子受体α、p53、少突胶质细胞转录因子2（OLIG 2）和R132 H突变的异柠檬酸脱氢酶1的高表达水平。免疫组化可将胶质瘤分为4种亚型。大多数低级别胶质瘤是前神经亚型，即p53高表达（63%的II级）。具有高EGFR和低p53表达的经典亚型在GBM中最常见（39%），其次是前神经（29%）和间充质（具有高CD 44和MERTK表达）（29%）亚型，该频率与先前发表的基于分子遗传学的数据一致。评估EGFR、CD 44、MERTK、p53和OLIG 2这五种蛋白的表达足以对胶质瘤进行亚型分型，并且可以推荐用于低级别和高级别胶质瘤的临床实践。
In 2010, four subtypes (classical, proneural, mesenchymal, and neural) of glioblastoma multiforme (GBM) were defined by molecular genetic analyses. The objective of this study was to assess whether gliomas, independently of the type and grade, could be subdivided into protein-based subtypes. A tissue microarray (TMA) approach was applied to incorporate tissue samples of low-grade and high-grade gliomas into five TMAs. High expression levels of epidermal growth factor receptor (EGFR), CD44, c-MER proto-oncogene tyrosine kinase (MERTK), platelet-derived growth factor receptor α, p53, oligodendrocyte transcription factor 2 (OLIG2) and isocitrate dehydrogenase 1 with the R132H mutation were assessed using immunohistochemistry (IHC). Glioma could be subdivided into four subtypes by IHC. The majority of the low-grade gliomas were of the proneural subtype, i.e. high p53 expression (63% of grade II). The classical subtype, with high EGFR and low p53 expression, was most common in GBMs (39%), followed by the proneural (29%) and mesenchymal (with high CD44 and MERTK expression) (29%) subtypes, a frequency that is in line with previously published data based on molecular genetics. Assessment of the expression of the five proteins EGFR, CD44, MERTK, p53 and OLIG2 is sufficient for subtyping gliomas, and can be recommended for implementation in clinical practice for both low-grade and high-grade gliomas.